Regulatory Approval
AstraZeneca Pharma India Receives CDSCO Approval for Additional Calquence Indication in Mantle Cell Lymphoma
NSE
astrazen
BSE
506820
AstraZeneca Pharma India Limited announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO) for import, sale, and distribution of Acalabrutinib maleate tablets 100 mg (Calquence®) for an additional indication in adult patients with previously untreated mantle cell lymphoma (MCL).
PRICE-SENSITIVE TRIGGER
Event: CDSCO Approval for Additional Calquence Indication
Type: Regulatory Approval / Product Commercial Expansion
Impact: Positive
Immediate Effect: The approval expands AstraZeneca’s oncology portfolio in India and enables commercialization of Calquence® for an additional treatment indication in mantle cell lymphoma patients.
Key Metrics:
- Approved Product: Acalabrutinib maleate tablets 100 mg
- Brand Name: Calquence®
- Therapy Area: Oncology / Hematology
- Target Indication: Mantle Cell Lymphoma (MCL)
- Approval Authority: CDSCO, Directorate General of Health Services, Government of India
- Approval Date Received: May 20, 2026
Highlight Metric:
- CDSCO approved Calquence® for treatment of previously untreated mantle cell lymphoma patients not eligible for autologous stem cell transplant.
What Happened ?
AstraZeneca Pharma India Limited informed stock exchanges that it received permission from the Central Drugs Standard Control Organization (CDSCO) for import, sale, and distribution of Acalabrutinib maleate tablets 100 mg, marketed under the brand name Calquence®, for an additional indication in India.
The approval allows use of Acalabrutinib in combination with:
- Bendamustine
- Rituximab (BR)
for treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT).
The company stated that this approval paves the way for marketing the product in India for the newly approved indication, subject to related statutory approvals wherever applicable.
Key Details
Drug Approval & Oncology Expansion:
- Drug approved:
- Acalabrutinib maleate tablets 100 mg.
- Brand name:
- Calquence®.
- Approval granted by:
- Central Drugs Standard Control Organization (CDSCO).
- Directorate General of Health Services.
- Government of India.
- Approval purpose:
- Import, sale, and distribution in India.
- Additional approved indication:
- Previously untreated mantle cell lymphoma (MCL).
- Eligible patient category:
- Adult patients not eligible for autologous stem cell transplant (ASCT).
- Combination therapy approved with:
- Bendamustine.
- Rituximab (BR).
- Therapeutic focus:
- Oncology / blood cancer treatment.
- Strategic significance:
- Strengthens AstraZeneca’s hematology and oncology portfolio in India.
- Company statement:
- Approval enables marketing of Calquence® for additional indication subject to statutory approvals.
Note:
- The approval expands treatment options available for mantle cell lymphoma patients in India and supports AstraZeneca’s oncology growth strategy in the Indian pharmaceutical market.
Risk Analysis
Summary:
- Although regulatory approval strengthens AstraZeneca’s oncology portfolio, commercial success depends on market adoption, pricing dynamics, physician acceptance, and competitive oncology therapies.
Key Risks:
- Product uptake depends on physician prescription trends.
- Competition from alternative lymphoma therapies may affect market share.
- Pricing and reimbursement challenges may impact commercial scalability.
- Regulatory compliance and pharmacovigilance obligations remain critical.
- Import and distribution approvals may involve operational timelines.
- Oncology drug commercialization involves high marketing and awareness costs.
Worst Case Scenario:
- If market adoption remains weak or competitive therapies gain preference, the commercial contribution from the newly approved indication may remain limited.
Risk Level: Low
Company Commentary
- AstraZeneca confirmed receipt of CDSCO approval for additional indication of Calquence®.
- The company stated that the approval covers adult mantle cell lymphoma patients not eligible for ASCT.
- Management highlighted that Acalabrutinib will be used in combination with Bendamustine and Rituximab.
- The company stated that the approval paves the way for commercialization in India subject to applicable statutory approvals.
Official Exchange Filing: AstraZeneca Pharma India Limited